ITF Therapeutics Presents New Givinostat Data in Duchenne Muscular Dystrophy at 2025 NMSG Annual Meeting

ITF Therapeutics Presents New Givinostat Data in Duchenne Muscular Dystrophy at 2025 NMSG Annual Meeting

By, Admin 27 September 2025

Stresa, Italy – ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, announced new data on givinostat (DUVYZAT®) for Duchenne muscular dystrophy (DMD) at the 2025 Neuromuscular Study Group (NMSG) Annual Scientific Meeting.

The presentations highlight insights from the pivotal Phase 3 EPIDYS trial and related studies, including flexible dosing, safety, biomarker correlations, and respiratory outcomes.

Key Data Highlights

  • Weight-Based Flexible Dosing (Poster #1213): Analysis of dose adjustments in EPIDYS showed impact on 4-stair climb (4SC) time and North Star Ambulatory Assessment (NSAA) scores at week 72.
  • Thrombocytopenia Characterization (Poster #1207): Expanded analysis of platelet count changes confirmed thrombocytopenia as a manageable, dose-related adverse event.
  • Vastus Lateralis Fat Fraction (Poster #1211): VLFF changes correlated with functional outcomes, reinforcing its role as a potential biomarker for disease progression.
  • Respiratory Function (Poster #1208): Data from EPIDYS and extension studies suggest slower decline in forced vital capacity (FVC) compared with natural history controls.

Expert Perspectives

“These presentations reflect our focus on supporting clinicians with data that clarify the benefit-risk profile of givinostat, including flexible dosing strategies,”

  • Scott Baver, Ph.D., VP, Head of Medical Affairs, ITF Therapeutics.

“Together, these findings deepen our understanding of givinostat’s use in DMD and may help guide clinical decision-making,”

  • Dr. Aravindhan Veerapandiyan, University of Arkansas for Medical Sciences.

About DUVYZAT® (givinostat)

  • Class: Oral histone deacetylase (HDAC) inhibitor
  • Indication: Approved for DMD in patients ≥6 years
  • Mechanism: Regulates excessive HDAC activity in dystrophic muscle, helping restore gene expression and muscle repair processes independent of dystrophin mutation type.

Safety Profile

  • Common adverse reactions (>5%): Diarrhea, abdominal pain, thrombocytopenia, nausea/vomiting, hypertriglyceridemia, pyrexia, myalgia, rash, arthralgia, fatigue, constipation, decreased appetite.
  • Warnings/Precautions: Monitor for hematologic changes, triglyceride elevations, gastrointestinal disturbances, and QTc prolongation. Regular ECG and blood count monitoring recommended.

About ITF Therapeutics and Italfarmaco

  • ITF Therapeutics LLC (launched 2024) is focused on rare diseases, with programs built in collaboration with advocacy and research communities.
  • Italfarmaco (founded 1938, Milan) is a private global pharma company with operations in 90+ countries, active in neurology, rare diseases, immuno-oncology, and cardiovascular care.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!